Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

5.2K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

7.1K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epigenetic Compound Library Screen Identifies Ibrutinib as an Inhibitor of Ovarian Clear Cell Carcinoma Viability.

Cancer medicine·2026
Same author

Repurposing of ivacaftor shows potential to treat ROR1 expressing high-grade serous ovarian cancer.

Therapeutic advances in medical oncology·2026
Same author

Drug repurposing in gynaecological cancers: Proven drugs for new challenges.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2025
Same author

Pancreatic transdifferentiation of NOD mouse livers prevented development of hyperglycemia.

Molecular therapy : the journal of the American Society of Gene Therapy·2025
Same author

Functions and Mechanisms of Diabetes-Linked Transcription Factors.

Frontiers in bioscience (Landmark edition)·2025
Same author

Revealing genetic drivers of ovarian cancer and chemoresistance: insights from whole-genome CRISPR-knockout library screens.

Cellular oncology (Dordrecht, Netherlands)·2025

Related Experiment Video

Updated: Jan 5, 2026

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.6K

Toward Systems Pathology for PTEN Diagnostics.

Nahal Haddadi1, Glena Travis1, Najah T Nassif1,2

  • 1School of Life Sciences, University of Technology Sydney, Ultimo, New South Wales 2007, Australia.

Cold Spring Harbor Perspectives in Medicine
|October 17, 2019
PubMed
Summary
This summary is machine-generated.

Germline PTEN mutations increase cancer risk and are linked to various syndromes. A systems pathology approach integrating clinical and molecular data can improve PTEN mutation diagnostics and patient management.

More Related Videos

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

2.5K
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.6K

Related Experiment Videos

Last Updated: Jan 5, 2026

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.6K
Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

2.5K
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.6K

Area of Science:

  • Oncology
  • Genetics
  • Systems Pathology

Background:

  • Germline PTEN alterations are linked to PTEN hamartoma tumor syndromes, including Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, Proteus syndromes, and autism spectrum disorder.
  • Germline PTEN mutations are associated with an elevated risk of specific cancer types.
  • Somatic PTEN variants are prevalent in various malignancies.

Purpose of the Study:

  • To introduce a systems pathology approach for PTEN diagnostics.
  • To enhance the clinical management of patients with PTEN mutations by integrating clinical and molecular pathology data.

Main Methods:

  • Review of existing literature on PTEN germline and somatic alterations.
  • Discussion of integrating clinical and molecular pathology data for improved diagnostics.

Main Results:

  • Germline PTEN mutation detection can guide cancer surveillance strategies.
  • Somatic PTEN mutations may inform disease course prediction.
  • PTEN's role in the PI3K/AKT/mTOR pathway suggests therapeutic implications.

Conclusions:

  • A systems pathology approach offers a framework for improved PTEN diagnostics.
  • Integrating diverse data types can optimize patient management for PTEN-related conditions.
  • Understanding PTEN alterations can uncover novel therapeutic avenues.